Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha,alpha-Dibromo-D-camphor is a synthetic dibrominated derivative of D-camphor with the molecular formula C10H14Br2O and a molecular weight of 310.03 g/mol[1][5]. It is primarily used as an ingredient in topical pain-relieving products in combination with other agents such as capsaicin and menthol[2][4][8]. The compound is not widely recognized as a pharmaceutical agent on its own but may be present in over-the-counter external analgesic preparations. Its mechanism of action is not fully understood; it is believed to interact with various molecular targets due to the presence of bromine atoms that can influence reactivity and interactions with biomolecules through halogen bonding or structural modification[6]. There are no well-established primary indications for systemic use or evidence for development by major pharmaceutical companies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha,alpha-dibromo-D-camphor.